Real-world effectiveness of natalizumab treatment in patients with relapsing multiple sclerosis in Argentina and Chile.

Maria Celica Ysrraelit Alejandro Caride Vladimiro Sinay Mario Rivera Kindel Mario Javier Halfon Liliana Patrucco Raul Piedrabuena Vanina Eleonor Diaz Aragunde

Published in: Arquivos de neuro-psiquiatria (2021)

Natalizumab significantly reduced disease activity in PwRMS in Argentina and Chile, in clinical practice. Natalizumab also decreased the number of hospitalizations compared with pre-natalizumab treatment.

Keyphrases

multiple sclerosis
disease activity
white matter
systemic lupus erythematosus
rheumatoid arthritis
clinical practice
randomized controlled trial
rheumatoid arthritis patients
ankylosing spondylitis